1. Introduction
Breast cancer is the most commonly diagnosed disease in women worldwide, with an incidence of 2.3 million and 685,000 deaths reported in 2020 [1]. Breast cancer subtypes are generally classified into estrogen receptor positive (ER+), progesterone receptor positive (PR+), human epidermal growth factor receptor 2 positive (HER2+), and triple-negative [2,3]. Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancer cases and is the breast cancer type that does not express HER2, ER, and PR [2,3]. TNBC has a higher rate of distant recurrence and a worse overall prognosis than HER2- or hormone receptor-positive breast cancer types [3]. TNBC does not respond to anticancer drugs that target hormone receptors, such as anastrozole and tamoxifen, or HER2, such as lapatinib and trastuzumab [2]. The current standard treatments for TNBC are surgical resection, radiation therapy, and chemotherapy. Taxanes and anthracyclines, including paclitaxel, docetaxel, doxorubicin, and epirubicin, are chemotherapeutic drugs approved for the treatment of TNBC [4]. To improve the treatment outcomes of TNBC, poly (ADP-ribose) polymerase (PARP) inhibitors, such as talazoparib and olaparib, as well as pembrolizumab, an immune checkpoint inhibitor, can be additionally used in combination [5,6,7]. However, the heterogeneity and complexity of TNBC have led to resistance to clinically approved therapies [8]. The development of drug resistance leads to relapse and therapeutic failure in patients with TNBC [9]. Therefore, it is urgent to find new types of potential anticancer drugs that effectively suppress the proliferation and metastasis of TNBC cells.
Apoptosis evasion is a critical feature of malignant tumor cells [10]. Therefore, the promotion of cancer cell apoptosis has become a central strategy in anticancer therapy. The distinct changes in cellular morphology and biochemical events, including cell shrinkage, chromatin condensation, DNA fragmentation, generation of reactive oxygen species (ROS), and loss of mitochondrial membrane potential, are key features of apoptosis [10,11]. The intrinsic and extrinsic pathways of apoptosis activate caspases, a family of cysteine proteases. Activated initiator caspases, such as caspase-8 and -9, cleave and activate downstream effector caspases, such as caspase-3 and -7, which execute cellular apoptosis by cleaving a variety of substrate proteins that control the cell cycle, DNA repair, and gene expression [12,13]. Therefore, novel compounds capable of activating the apoptotic pathways and central apoptosis mediators in TNBC cells can be considered potential anticancer agents for TNBC treatment.
The leading cause of death in patients with TNBC is distant metastases, which are particularly likely to recur and spread to the brain and lungs [14,15]. TNBC metastasis is closely related to abnormal induction of epithelial-mesenchymal transition (EMT) [16]. During EMT, the adhesion ability, polarity, and differentiation of epithelial cells decrease; however, their migration and invasion capacities increase [17]. EMT is triggered by several signaling pathways, including transforming growth factor-β, Wnt/β-catenin, Notch, and Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) [18,19]. These signaling pathways activate transcription factors such as Slug, Snail, Twist, and ZEB1, which downregulate the expression of the epithelial markers E-cadherin, Claudin-1, and cytokeratin and upregulate the expression of the mesenchymal markers N-cadherin and vimentin [20]. Thus, targeting EMT may be an effective method to prevent TNBC metastasis and recurrence.
Bufotalin, a steroid bufadienolide (C26H36O6), is one of the main active ingredients in the traditional Chinese medicine Chan Su, which is a dried secretion from the skin and parotid venom glands of toads (B. gargarizans) (Figure 1A) [21]. Chan Su has long been used as a cardiotonic, antibacterial, antiviral, antitumor, analgesic, and local anesthetic agent in China and other Asian countries [21]. Previous studies have shown that bufotalin exhibits antiviral, anti-inflammatory, and anticancer activities [22,23,24]. Bufotalin ameliorates chronic inflammatory autoimmune diseases by inhibiting Th17 polarization and cytokine secretion [23]. Bufotalin also has broad anti-coronavirus activity [24]. The antitumor effects of bufotalin have been demonstrated in various cancer cell lines [25]. Bufotalin promotes apoptosis in the liver cancer cell line Hep3B by activating caspases and apoptosis-inducing factor (AIF) [26]. It also suppresses the proliferation of A375 melanoma cells by causing apoptosis and cell cycle arrest through the inactivation of the serine/threonine kinase AKT [27]. In addition, bufotalin triggers apoptosis mediated by p53 in esophageal squamous cell carcinoma cells and leads to ferroptosis by promoting the degradation of glutathione peroxidase 4 in A549 non-small cell lung cancer cells [28,29]. However, no studies have demonstrated that bufotalin inhibits the proliferation and metastasis of TNBC cells. In the current study, we assessed the antiproliferative and antimetastatic effects of bufotalin on TNBC cells for the first time. In addition, it was confirmed that the anticancer activity of bufotalin against TNBC cells was related to the regulation of the apoptosis pathway, EMT, and STAT3 signaling.
2. Results
2.1. Bufotalin Inhibits TNBC Cell Proliferation
To investigate whether bufotalin affects the proliferation of TNBC cells, the human MDA-MB-231 and HCC1937 TNBC cell lines were treated with bufotalin at the indicated doses (0–10 μM) for 72 h. Cell proliferation was then measured using a luminescent adenosine triphosphate (ATP) detection assay. Bufotalin dose-dependently inhibited the proliferation of MDA-MB-231 and HCC1937 TNBC cells with 78 and 370 nM of the IC50 value, respectively (Figure 1B). Next, we evaluated the effect of bufotalin on the colony-forming ability of MDA-MB-231 and HCC1937 cells. Bufotalin treatment dose-dependently suppressed clonogenic growth of both TNBC cell lines (Figure 1C). These results demonstrate that bufotalin inhibits the proliferation of TNBC cells.
2.2. Bufotalin Induces Cell Cycle Arrest and Apoptosis in TNBC Cells
To determine whether bufotalin inhibited TNBC cell proliferation through regulation of the cell cycle and apoptosis, we first investigated the effect of bufotalin on cell cycle distribution using flow cytometry. MDA-MB-231 and HCC1937 TNBC cell lines were treated with 200, 400, 800, and 1000 nM of bufotalin for 72 h. Compared to the untreated cells, treatment with bufotalin increased the S and G2/M phase cell populations in MDA-MB-231 and HCC1937 cells, respectively, in a dose-dependent manner (Figure 2A). These results indicate that bufotalin inhibited TNBC cell proliferation by inducing cell cycle arrest at the S phase in MDA-MB-231 cells and the G2/M phase in HCC1937 cells. The effect of bufotalin on cellular apoptosis was analyzed using flow cytometry. Bufotalin treatment for 72 h increased the proportion of apoptotic MDA-MB-231 and HCC1937 cells compared to that in untreated control cells in a dose-dependent manner (Figure 2B). Thus, the anti-proliferative effect of bufotalin on TNBC cells may be related to cell cycle arrest and induction of apoptosis.
2.3. Bufotalin Activates Caspase-Mediated Apoptotic Pathway in TNBC Cells
To further verify the TNBC cell apoptosis induced by bufotalin, we first investigated whether bufotalin causes nuclear morphological changes in MDA-MB-231 and HCC1937 TNBC cell lines. Staining of nuclei with 4′,6-diamidino-2-phenylindole (DAPI) showed that bufotalin treatment for 48 h induced nuclear condensation and fragmentation in both the cell lines (Figure 3A). Next, to determine whether bufotalin affects the generation of ROS, which plays a central role in inducing apoptosis, intracellular ROS levels were measured using the fluorogenic indicator dichloro-dihydro-fluorescein diacetate (DCFH-DA). Bufotalin treatment for 48 h significantly increased ROS generation in MDA-MB-231 and HCC1937 cells in a dose-dependent manner (Figure 3B). We further evaluated the effect of bufotalin on the expression of caspases, which are key mediators of apoptosis and are activated by proteolytic cleavage. Active caspase-9 triggers cleavage and activation of downstream caspase-3. Subsequently, caspase-3 promotes apoptosis by cleaving the DNA repair enzyme PARP [30]. Western blot analysis revealed that bufotalin treatment for 48 h increased the expression levels of cleaved caspase-9, caspase-3, and PARP in MDA-MB-231 and HCC1937 cells (Figure 3C). These results suggest that bufotalin induces apoptosis by activating the caspase-mediated apoptotic pathway in TNBC cells.
2.4. Bufotalin Suppresses TNBC Cell Migration and Invasion
In addition to the antiproliferative activity of bufotalin against TNBC cells, we investigated whether bufotalin could inhibit the metastatic ability of TNBC cells. A wound-healing assay was employed to measure TNBC cell migration. Wound closure by MDA-MB-231 and HCC1937 TNBC cell lines was observed after 24 and 12 h of incubation, respectively. Bufotalin treatment significantly reduced the migration of both TNBC cell lines compared to that of the untreated cells (Figure 4A). Next, the effect of bufotalin on the invasion ability of TNBC cells was evaluated using a transwell chamber system coated with Matrigel matrix. Bufotalin treatment for 24 h inhibited the invasiveness of MDA-MB-231 and HCC1937 TNBC cell lines in a dose-dependent manner (Figure 4B). These results suggest that bufotalin effectively suppresses TNBC metastasis.
2.5. Bufotalin Modulates Major Molecular Markers Involved in TNBC Metastasis
To determine the molecular mechanism by which bufotalin suppresses the metastasis of TNBC cells, we assessed whether bufotalin affects the expression of key molecular markers, including EMT regulators, matrix metalloproteinases (MMPs), and integrin α6, which play important roles in TNBC metastasis [16,31,32]. After bufotalin treatment of MDA-MB-231 and HCC1937 cells, expression of the epithelial cell-specific marker E-cadherin was upregulated, whereas expression of the mesenchymal cell-specific markers N-cadherin and vimentin was downregulated (Figure 5). In addition, bufotalin significantly reduced the expression of MMP-2, MMP-9, and integrin α6 in both TNBC cell lines (Figure 5). These data indicate that the anti-metastatic activity of bufotalin in TNBC cells may be associated with the downregulation of EMT, MMPs, and integrins that contribute to TNBC cell migration and invasion.
Aberrant STAT3 signaling is a crucial driver of TNBC proliferation, metastasis, and chemoresistance [18]. Therefore, we examined whether bufotalin regulates the activation of STAT3 in TNBC cells. Bufotalin potently inhibited the phosphorylation of STAT3 in MDA-MB-231 and HCC1937 cells without significantly inhibiting the total protein levels of STAT3 (Figure 5). In addition, colivelin, a STAT3 activator, partially restored the inhibitory effects of bufotalin on STAT3 phosphorylation and cell viability in both TNBC cell lines (Supplementary Figures S1 and S2). These results suggest that bufotalin may exhibit anticancer activity against TNBC cells via the downregulation of the STAT3 signaling pathway.
3. Discussion
TNBC is a highly aggressive and metastatic subtype of breast cancer with high mortality rates and no effective targeted therapy [2,3]. Several chemotherapeutic drugs, such as taxanes and anthracyclines, in combination with PARP and immune checkpoint inhibitors, are available for the treatment of TNBC; however, they exhibit low efficacy and side effects [4,5,6,7]. Therefore, the search for novel anticancer agents is urgently required to achieve effective chemotherapy for TNBC.
Bufadienolides, including telocinobufagin, bufotalin, bufalin, cinobufotalin, and cinobufagin, have been isolated and identified in traditional Chinese medicine Chan Su (dried toad skin secretions) [33]. Accumulating evidence has revealed the antitumor activity of bufadienolides in several cancer types. Multiple studies have focused on the antitumor effects of bufadienolides in breast cancer cells [25]. Bufalin suppressed the growth of the human breast cancer cell lines MCF-7 and MDA-MB-231 by triggering necroptosis through the ROS-mediated receptor-interacting protein (RIP)1/RIP3/PARP-1 pathways [34]. Moreover, bufalin significantly promoted TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in MCF-7 and MDA-MB-231 cells by downregulating the STAT3/myeloid cell leukemia-1 pathway [35]. Cinobufotalin exhibited anticancer activity in MCF-7 cells by modulating the expression of the non-receptor tyrosine kinase SRC and the cyclin-dependent kinase inhibitor 2A [36]. Cinobufagin induces apoptosis and G1 phase arrest in MCF-7 cells by affecting Bax and Bcl-2 expression [37]. Telocinobufagin inhibited the migration and invasion of 4T1 murine breast cancer cells by repressing EMT through downregulation of the phosphoinositide-3-kinase (PI3K)/AKT/extracellular signal-regulated kinase (ERK)/Snail pathway [38]. However, the anticancer effect and underlying molecular mechanisms of action of bufotalin in TNBC cells have not yet been fully elucidated. In the current study, we demonstrated, for the first time, the antiproliferative and antimetastatic activities of bufotalin against TNBC cells through the regulation of the apoptotic pathway, EMT, and STAT3 signaling.
Our results showed that bufotalin potently inhibited TNBC cell proliferation by inducing cell cycle arrest and apoptosis. Bufotalin arrested the cell cycle in the S and G2/M phases in the MDA-MB-231 and HCC1937 cell lines, respectively. It also promoted apoptotic cell death by activating key regulatory mechanisms of apoptosis, including nuclear fragmentation, increased ROS production, and activation of the caspase cascade in both TNBC cell lines. Bufotalin effectively suppressed the migration and invasion of MDA-MB-231 and HCC1937 cells. Notably, the anti-metastatic activity of bufotalin in TNBC cells is related to the downregulation of EMT, MMPs, and integrin α6. EMT is an important step in TNBC metastasis [16]. Bufotalin reverses EMT by augmenting the expression of the epithelial cell marker E-cadherin and reducing the expression of the mesenchymal cell markers N-cadherin and vimentin in MDA-MB-231 and HCC1937 cells. MMPs are a family of zinc-dependent proteases that degrade the extracellular matrix (ECM) and play important roles in TNBC metastasis [32]. Bufotalin decreased the expression of MMP-2 and MMP-9, the major MMPs that are highly expressed in TNBC. Integrins are transmembrane receptors that play important roles in mediating cell-cell and cell-ECM adhesion and regulate diverse cellular responses, including cell survival, proliferation, migration, and invasion [39]. In addition, the aberrant expression of integrins, including α6 and β1, is closely linked to the invasiveness and metastasis of cancer cells, including breast cancer [39]. Bufotalin markedly inhibited integrin α6 expression in both TNBC cell lines. Therefore, our data demonstrate the antiproliferative and antimetastatic activities of bufotalin in TNBC cells and identify the anticancer molecular mechanisms involved in the regulation of caspase-mediated apoptosis, EMT, MMP, and integrins.
Recent studies demonstrated that STAT3 plays a pivotal role in TNBC growth and metastasis [18]. STAT3 acts as a transcriptional activator that regulates multiple target oncogenes and promotes the proliferation, anti-apoptosis, angiogenesis, metastasis, and chemoresistance of cancer cells [40,41]. It has been reported that STAT3-mediated breast cancer cell metastasis is associated with the upregulation of vimentin, MMP-2, and MMP-9 [42]. Inhibition of STAT3 signaling also reduces the expression of EMT inducers and MMPs in breast cancer cells [43]. STAT3 activation promotes integrin-mediated cell adhesion and intracellular signaling in breast cancer cells [44]. Thus, STAT3 may be an upstream regulator contributing to the activation of apoptotic evasion, EMT, MMPs, and integrins in TNBC cells. Our results showed that bufotalin significantly downregulated STAT3 signaling in both the MDA-MB-231 and HCC1937 cell lines, suggesting that bufotalin suppresses TNBC cell proliferation and metastasis by blocking the STAT3 signaling pathway (Figure 6).
Collectively, our findings suggest that bufotalin is a promising anticancer agent that effectively suppresses TNBC cell growth and metastasis. Recently, Chan Su was approved by the Chinese FDA as injections, capsules, oral solutions, and tablets [25]. Clinically, Chan Su is used for the treatment of severe upper and lower respiratory tract infections, chronic hepatitis B, and several cancer types, including liver, prostate, and colorectal cancers [45,46]. However, the clinical efficacy and safety of the components of Chan Su, including bufotalin, remain unclear. Therefore, further in vivo studies are required to definitively verify the efficacy and safety of bufotalin for the treatment of TNBC.
4. Materials and Methods
4.1. Materials
Bufotalin was obtained from MedChemExpress (South Brunswick, NJ, USA). DMEM, RPMI-1640, and trypsin were obtained from HyClone (Marlborough, MA, USA). Fetal bovine serum (FBS) and penicillin/streptomycin/amphotericin B solution were obtained from R&D Systems (Minneapolis, MN, USA) and Lonza (Walkersville, MD, USA), respectively. Dichlorodihydrofluorescein diacetate (DCFH-DA), crystal violet, eosin, hematoxylin, gelatin, and 4’,6-diamidine-2’-phenylindole dihydrochloride (DAPI) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Ibidi culture inserts and Transwell chamber inserts were obtained from ibidi GmbH (Munich, Germany) and SPL Life Sciences (Pocheon, Republic of Korea), respectively. Matrigel and polyvinylidene difluoride (PVDF) membranes were obtained from Corning (Tewksbury, MA, USA) and EMD Millipore (Hayward, CA, USA), respectively. Antibodies for detecting phospho-STAT3 (Tyr705, #9145), STAT3 (#9139), cleaved PARP (#9542), MMP-2 (#4022), MMP-9 (#3852), cleaved caspase-3 (#9661), cleaved caspase-9 (#9501), integrin α6 (#3750), β-actin (#4967), mouse IgG (#7076), and rabbit IgG (#7074) were obtained from Cell Signaling Technology (Danvers, MA, USA). Antibodies against vimentin (#A11952), N-cadherin (#A0433), and E-cadherin (#A11492) were obtained from ABclonal (Woburn, MA, USA). An enhanced chemiluminescence (ECL) kit was obtained from Bio-Rad Laboratories (Hercules, CA, USA).
4.2. Cell Culture
Human TNBC cell lines MDA-MB-231 (KCLB No. 30026) and HCC1937 (KCLB No. 9S1937) were provided by the Korean Cell Line Bank (Seoul, Republic of Korea). Each cell line was identified by STR analysis. MDA-MB-231 and HCC1937 cells were grown in DMEM and RPMI-1640 media containing 10% FBS and 1% penicillin/streptomycin/amphotericin B, respectively. The TNBC cell lines were incubated at 37 °C in a humidified CO2 incubator with 5% CO2 (Thermo Scientific, Vantaa, Finland).
4.3. Cell Proliferation Assay
MDA-MB-231 and HCC1937 cells were inoculated at a density of 3 × 103 cells per well in 96-white-well culture plates. The TNBC cells were incubated for 72 h after treatment with bufotalin (0–10 μM). To measure cell proliferation, the CellTiter-Glo® 2.0 Cell Viability Assay (Promega, Madison, WI, USA) was performed according to the manufacturer’s instructions [47]. Luminescence was measured using a BioTek multimode plate reader (Winooski, VT, USA). Calculation of IC50 was performed with GraphPad Prism 6 software (La Jolla, CA, USA).
4.4. Colony Formation Assay
MDA-MB-231 and HCC1937 cells were inoculated at a density of 1 × 103 cells per well in six-well culture plates. The TNBC cells were incubated for 14 days after treatment with bufotalin (50, 100, 200 nM). Formed cell colonies were fixed using a 3.7% formaldehyde solution and then washed with phosphate-buffered saline (PBS). After staining with 0.5% crystal violet solution for 15 min, visible cell colonies were observed and counted.
4.5. Cell Cycle Analysis
MDA-MB-231 and HCC1937 cells were inoculated at a density of 1 × 105 cells per well in 6-well culture plates. The TNBC cells were incubated for 72 h after treatment with bufotalin (200, 400, 800, 1000 nM). The cells were collected and then fixed using 70% ethanol at −20 °C for 3 h. The TNBC cells were washed with PBS and then stained by adding 200 µL of Muse® Cell Cycle reagent (Luminex, Austin, TX, USA) according to the manufacturer’s instructions [47]. The cell cycle profile of each sample was measured with the Guava® Muse® Cell Analyzer with MuseSoft_V1.8.0.3 (Luminex, Austin, TX, USA).
4.6. Analysis of Apoptotic Cell Death
MDA-MB-231 and HCC1937 cells were inoculated at a density of 1 × 105 cells per well in six-well culture plates. The TNBC cells were incubated for 72 h after treatment with bufotalin (200, 400, 800, 1000 nM). The cells were collected and then stained by adding 100 μL of Muse® Annexin V & Dead Cell reagent (Luminex, Austin, TX, USA) according to the manufacturer’s instructions [47]. The percentage of apoptotic cells was determined using the Guava® Muse® Cell Analyzer with MuseSoft_V1.8.0.3 (Luminex, Austin, TX, USA).
4.7. Analysis of Nuclear Morphology
MDA-MB-231 and HCC1937 cells were inoculated at a density of 5 × 104 cells per well in 24-well culture plates. The TNBC cells were incubated for 48 h after treatment with bufotalin (200, 400, 800, 1000 nM). After washing with PBS, the cells were treated with 20 μg/mL of DAPI and incubated for 1 h [48]. The stained cellular nuclei were observed using the Optinity KI-2000F fluorescence microscope (Korea Lab Tech, Seong Nam, Republic of Korea).
4.8. ROS Generation Analysis
MDA-MB-231 and HCC1937 cells were inoculated at a density of 5 × 104 cells per well in 24-well culture plates. The TNBC cells were incubated for 48 h after treatment with bufotalin (200, 400, 800, 1000 nM). The cells were washed with PBS and then treated with 20 μM of DCFH-DA [48]. After incubation for 20 min, intracellular ROS produced were detected using the Optinity KI-2000F fluorescence microscope (Korea Lab Tech, Seong Nam, Republic of Korea). To quantify the ROS levels, the intensity of DCF fluorescence was measured with the ImageJ 1.5 software program from NIH (Bethesda, MD, USA). The DCF fluorescence levels of untreated control cells were normalized to 100%.
4.9. Wound Healing Assay
After attaching ibidi culture inserts to each well, MDA-MB-231 and HCC1937 cells were inoculated at a density of 5 × 104 cells per insert in 24-well culture plates and then incubated for 24 h. The inserts were removed, and the cells were treated with bufotalin (200, 400 nM) for 12 or 24 h. The images of migrated cells were obtained at each time point (0, 6, 12, 24 h) using the Olympus optical microscope (Tokyo, Japan) at a magnification of 200×. The area of the gap was measured, and the cell migration results were expressed as a percentage of control.
4.10. Invasion Assay
The transwell chamber containing polycarbonate membrane inserts with 8.0 μm pore size was used to measure TNBC cell invasiveness [49]. The outside of the membrane insert was coated with 10 μL of gelatin (1 mg/mL) and dried at room temperature for 1 h. The inside of the membrane insert was then coated with 10 μL of Matrigel (3 mg/mL) and dried at room temperature for 1 h. MDA-MB-231 and HCC1937 cells were inoculated at a density of 5 × 104 cells per well in the upper chamber of the membrane insert, and bufotalin (200, 400 nM) was added to the lower chamber. After incubation for 24 h, the invaded cells were fixed using 70% methanol and then stained using hematoxylin and eosin (H&E). The images of invaded cells were taken using the Olympus optical microscope (Tokyo, Japan) at a magnification of 200×. The total invaded cells were counted, and cell invasion results were expressed as a percentage of control.
4.11. Western Blotting
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed to separate TNBC cell lysate samples prepared at equal protein concentrations according to molecular weight. The proteins separated on the gel were then transferred onto the PVDF membrane (pore size 0.2 μm) by electroblotting. To block the non-specific binding of antibodies, the transferred blots were incubated with 5% non-fat milk dissolved in Tris-buffered saline containing 1 × Tween-20 (TBST) for 1 h at room temperature with gentle agitation. For immunolabeling, the blots were incubated with specific primary antibodies (dilution 1:2000–1:10,000) at 4 °C overnight with gentle agitation. Thereafter, the membranes were washed thrice using TBST and then incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (dilution 1:3000) for 1 h at room temperature with gentle agitation. Subsequently, immunolabeling was detected by an ECL kit according to the manufacturer’s instructions [47]. The results were quantified by calculating the band intensity of the target protein relative to β-actin using the ImageJ 1.5 software program from NIH (Bethesda, MD, USA). The expression ratio of each target protein to β-actin in untreated control cells was normalized to onefold.
4.12. Statistical Analysis
Statistical analyses were done with ANOVA followed by Tukey’s post-hoc test using SPSS version 9.0 software (Chicago, IL, USA). A p < 0.05 was considered to indicate a statistically significant difference. Data are presented as the mean ± standard deviation (SD).
5. Conclusions
In summary, bufotalin suppressed the growth and metastasis of MDA-MB-231 and HCC1937 TNBC cell lines. Bufotalin induced cell cycle arrest and apoptosis and inhibited cell migration and invasion in both TNBC cells. Furthermore, our results demonstrated that the anticancer activity of bufotalin against TNBC cells was related to the regulation of the caspase-mediated apoptotic pathway, EMT, MMP, integrin, and STAT3 signaling. Therefore, bufotalin has the chemotherapeutic potential to effectively suppress TNBC.
Conceptualization, H.J.J. and S.J.P.; methodology, S.J.P.; software, H.J.J.; validation, H.J.J. and S.J.P.; formal analysis, S.J.P.; investigation, S.J.P.; resources, H.J.J.; data curation, H.J.J. and S.J.P.; writing—original draft preparation, S.J.P.; writing—review and editing, H.J.J.; visualization, S.J.P.; supervision, H.J.J.; project administration, H.J.J.; funding acquisition, H.J.J. All authors have read and agreed to the published version of the manuscript.
Not applicable.
Not applicable.
The data that support the findings of this study are available from the corresponding author upon reasonable request.
The authors declare no conflict of interest.
Not applicable.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Supplementary Materials
The following supporting information can be downloaded at:
References
1. Arnold, M.; Morgan, E.; Rumgay, H.; Mafra, A.; Singh, D.; Laversanne, M.; Vignat, J.; Gralow, J.R.; Cardoso, F.; Siesling, S. et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast; 2022; 66, pp. 15-23. [DOI: https://dx.doi.org/10.1016/j.breast.2022.08.010] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36084384]
2. Yin, J.; Zhu, C.; Wang, G.; Gu, J. Treatment for triple-negative breast cancer: An umbrella review of meta-analyses. Int. J. Gen. Med.; 2022; 15, pp. 5901-5914. [DOI: https://dx.doi.org/10.2147/IJGM.S370351] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35795302]
3. Onitilo, A.A.; Engel, J.M.; Greenlee, R.T.; Mukesh, B.N. Breast cancer subtypes based on ER/PR and Her2 expression: Comparison of clinicopathologic features and survival. Clin. Med. Res.; 2009; 7, pp. 4-13. [DOI: https://dx.doi.org/10.3121/cmr.2008.825]
4. Mandapati, A.; Lukong, K.E. Triple negative breast cancer: Approved treatment options and their mechanisms of action. J. Cancer Res. Clin. Oncol.; 2023; 149, pp. 3701-3719. [DOI: https://dx.doi.org/10.1007/s00432-022-04189-6]
5. Collignon, J.; Lousberg, L.; Schroeder, H.; Jerusalem, G. Triple-negative breast cancer: Treatment challenges and solutions. Breast Cancer; 2016; 8, pp. 93-107.
6. Thomas, R.; Al-Khadairi, G.; Decock, J. Immune checkpoint inhibitors in triple negative breast cancer treatment: Promising future prospects. Front. Oncol.; 2021; 10, 600573. [DOI: https://dx.doi.org/10.3389/fonc.2020.600573]
7. Luo, L.; Keyomarsi, K. PARP inhibitors as single agents and in combination therapy: The most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. Expert Opin. Investig. Drugs; 2022; 31, pp. 607-631. [DOI: https://dx.doi.org/10.1080/13543784.2022.2067527]
8. Bianchini, G.; Balko, J.M.; Mayer, I.A.; Sanders, M.E.; Gianni, L. Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol.; 2016; 13, pp. 674-690. [DOI: https://dx.doi.org/10.1038/nrclinonc.2016.66]
9. Longley, D.B.; Johnston, P.G. Molecular mechanisms of drug resistance. J. Pathol.; 2005; 205, pp. 275-292. [DOI: https://dx.doi.org/10.1002/path.1706]
10. Elmore, S. Apoptosis: A review of programmed cell death. Toxicol. Pathol.; 2007; 35, pp. 495-516. [DOI: https://dx.doi.org/10.1080/01926230701320337]
11. Cooper, E.H. The biology of cell death in tumours. Cell Tissue Kinet.; 1973; 6, pp. 87-95. [DOI: https://dx.doi.org/10.1111/j.1365-2184.1973.tb01597.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/4683351]
12. Kaufmann, S.H.; Earnshaw, W.C. Induction of apoptosis by cancer chemotherapy. Exp. Cell Res.; 2000; 256, pp. 42-49. [DOI: https://dx.doi.org/10.1006/excr.2000.4838] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10739650]
13. Singh, R.; Letai, A.; Sarosiek, K. Regulation of apoptosis in health and disease: The balancing act of BCL-2 family proteins. Nat. Rev. Mol. Cell Biol.; 2019; 20, pp. 175-193. [DOI: https://dx.doi.org/10.1038/s41580-018-0089-8] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30655609]
14. Yin, L.; Duan, J.J.; Bian, X.W.; Yu, S.C. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res.; 2020; 22, 61. [DOI: https://dx.doi.org/10.1186/s13058-020-01296-5] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32517735]
15. Wu, Q.; Siddharth, S.; Sharma, D. Triple negative breast cancer: A mountain yet to be scaled despite the triumphs. Cancers; 2021; 13, 3697. [DOI: https://dx.doi.org/10.3390/cancers13153697]
16. Grasset, E.M.; Dunworth, M.; Sharma, G.; Loth, M.; Tandurella, J.; Cimino-Mathews, A.; Gentz, M.; Bracht, S.; Haynes, M.; Fertig, E.J. et al. Triple-negative breast cancer metastasis involves complex epithelial-mesenchymal transition dynamics and requires vimentin. Sci. Transl. Med.; 2022; 14, eabn7571. [DOI: https://dx.doi.org/10.1126/scitranslmed.abn7571]
17. Pastushenko, I.; Blanpain, C. EMT transition states during tumor progression and metastasis. Trends Cell Biol.; 2019; 29, pp. 212-226. [DOI: https://dx.doi.org/10.1016/j.tcb.2018.12.001]
18. Qin, J.J.; Yan, L.; Zhang, J.; Zhang, W.D. STAT3 as a potential therapeutic target in triple negative breast cancer: A systematic review. J. Exp. Clin. Cancer Res.; 2019; 38, 195. [DOI: https://dx.doi.org/10.1186/s13046-019-1206-z]
19. Buyuk, B.; Jin, S.; Ye, K. Epithelial-to-mesenchymal transition signaling pathways responsible for breast cancer metastasis. Cell. Mol. Bioeng.; 2021; 15, pp. 1-13. [DOI: https://dx.doi.org/10.1007/s12195-021-00694-9]
20. Chen, T.; You, Y.; Jiang, H.; Wang, Z.Z. Epithelial-mesenchymal transition (EMT): A biological process in the development, stem cell differentiation, and tumorigenesis. J. Cell. Physiol.; 2017; 232, pp. 3261-3272. [DOI: https://dx.doi.org/10.1002/jcp.25797]
21. Ye, M.; Guo, D.A. Analysis of bufadienolides in the Chinese drug ChanSu by high-performance liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom.; 2005; 19, pp. 1881-1892. [DOI: https://dx.doi.org/10.1002/rcm.1989] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15945036]
22. Zhang, D.M.; Liu, J.S.; Tang, M.K.; You, A.; Cao, H.H.; Jiang, L.; Chan, J.Y.; Tian, H.Y.; Fung, K.P.; Ye, W.C. Bufotalin from Venenum Bufonis inhibits growth of multidrug resistant HepG2 cells through G2/M cell cycle arrest and apoptosis. Eur. J. Pharmacol.; 2012; 692, pp. 19-28. [DOI: https://dx.doi.org/10.1016/j.ejphar.2012.06.045]
23. Huang, Y.; Yang, G.; Fei, J.; Wu, Y.; Yan, J. Bufotalin ameliorates experimental Sjögren’s syndrome development by inhibiting Th17 generation. Naunyn Schmiedebergs Arch. Pharmacol.; 2020; 393, pp. 1977-1985. [DOI: https://dx.doi.org/10.1007/s00210-020-01817-1] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31950221]
24. Jin, Y.H.; Jeon, S.; Lee, J.; Kim, S.; Jang, M.S.; Park, C.M.; Song, J.H.; Kim, H.R.; Kwon, S. Broad spectrum antiviral properties of cardiotonic steroids used as potential therapeutics for emerging coronavirus infections. Pharmaceutics; 2021; 13, 1839. [DOI: https://dx.doi.org/10.3390/pharmaceutics13111839] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34834252]
25. Jia, J.; Li, J.; Zheng, Q.; Li, D. A research update on the antitumor effects of active components of Chinese medicine ChanSu. Front. Oncol.; 2022; 12, 1014637. [DOI: https://dx.doi.org/10.3389/fonc.2022.1014637]
26. Su, C.L.; Lin, T.Y.; Lin, C.N.; Won, S.J. Involvement of caspases and apoptosis-inducing factor in bufotalin-induced apoptosis of Hep 3B cells. J. Agric. Food Chem.; 2009; 57, pp. 55-61. [DOI: https://dx.doi.org/10.1021/jf802769g]
27. Pan, Z.; Qu, C.; Chen, Y.; Chen, X.; Liu, X.; Hao, W.; Xu, W.; Ye, L.; Lu, P.; Li, D. et al. Bufotalin induces cell cycle arrest and cell apoptosis in human malignant melanoma A375 cells. Oncol. Rep.; 2019; 41, pp. 2409-2417. [DOI: https://dx.doi.org/10.3892/or.2019.7032]
28. Lin, S.; Lv, J.; Peng, P.; Cai, C.; Deng, J.; Deng, H.; Li, X.; Tang, X. Bufadienolides induce p53-mediated apoptosis in esophageal squamous cell carcinoma cells in vitro and in vivo. Oncol. Lett.; 2018; 15, pp. 1566-1572. [DOI: https://dx.doi.org/10.3892/ol.2017.7457]
29. Zhang, W.; Jiang, B.; Liu, Y.; Xu, L.; Wan, M. Bufotalin induces ferroptosis in non-small cell lung cancer cells by facilitating the ubiquitination and degradation of GPX4. Free Radic. Biol. Med.; 2022; 180, pp. 75-84. [DOI: https://dx.doi.org/10.1016/j.freeradbiomed.2022.01.009]
30. Los, M.; Mozoluk, M.; Ferrari, D.; Stepczynska, A.; Stroh, C.; Renz, A.; Herceg, Z.; Wang, Z.Q.; Schulze-Osthoff, K. Activation and caspase-mediated inhibition of PARP: A molecular switch between fibroblast necrosis and apoptosis in death receptor signaling. Mol. Biol. Cell; 2002; 13, pp. 978-988. [DOI: https://dx.doi.org/10.1091/mbc.01-05-0272]
31. Felding-Habermann, B.; O’Toole, T.E.; Smith, J.W.; Fransvea, E.; Ruggeri, Z.M.; Ginsberg, M.H.; Hughes, P.E.; Pampori, N.; Shattil, S.J.; Saven, A. et al. Integrin activation controls metastasis in human breast cancer. Proc. Natl. Acad. Sci. USA; 2001; 98, pp. 1853-1858. [DOI: https://dx.doi.org/10.1073/pnas.98.4.1853]
32. Li, H.; Qiu, Z.; Li, F.; Wang, C. The relationship between MMP-2 and MMP-9 expression levels with breast cancer incidence and prognosis. Oncol. Lett.; 2017; 14, pp. 5865-5870. [DOI: https://dx.doi.org/10.3892/ol.2017.6924] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29113219]
33. El-Seedi, H.R.; Yosri, N.; El-Aarag, B.; Mahmoud, S.H.; Zayed, A.; Du, M.; Saeed, A.; Musharraf, S.G.; El-Garawani, I.M.; Habib, M.R. et al. Chemistry and the potential antiviral, anticancer, and anti-inflammatory activities of cardiotonic steroids derived from toads. Molecules; 2022; 27, 6586. [DOI: https://dx.doi.org/10.3390/molecules27196586] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36235123]
34. Li, Y.; Tian, X.; Liu, X.; Gong, P. Bufalin inhibits human breast cancer tumorigenesis by inducing cell death through the ROS-mediated RIP1/RIP3/PARP-1 pathways. Carcinogenesis; 2018; 39, pp. 700-707. [DOI: https://dx.doi.org/10.1093/carcin/bgy039] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29546393]
35. Dong, Y.; Yin, S.; Li, J.; Jiang, C.; Ye, M.; Hu, H. Bufadienolide compounds sensitize human breast cancer cells to TRAIL-induced apoptosis via inhibition of STAT3/Mcl-1 pathway. Apoptosis; 2011; 16, pp. 394-403. [DOI: https://dx.doi.org/10.1007/s10495-011-0573-5] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21259053]
36. Li, J.; Rong, M.H.; Dang, Y.W.; He, R.Q.; Lin, P.; Yang, H.; Li, X.J.; Xiong, D.D.; Zhang, L.J.; Qin, H. et al. Differentially expressed gene profile and relevant pathways of the traditional Chinese medicine cinobufotalin on MCF-7 breast cancer cells. Mol. Med. Rep.; 2019; 19, pp. 4256-4270. [DOI: https://dx.doi.org/10.3892/mmr.2019.10062]
37. Zhu, L.; Chen, Y.; Wei, C.; Yang, X.; Cheng, J.; Yang, Z.; Chen, C.; Ji, Z. Anti-proliferative and pro-apoptotic effects of cinobufagin on human breast cancer MCF-7 cells and its molecular mechanism. Nat. Prod. Res.; 2018; 32, pp. 493-497. [DOI: https://dx.doi.org/10.1080/14786419.2017.1315575]
38. Gao, Y.; Shi, L.; Cao, Z.; Zhu, X.; Li, F.; Wang, R.; Xu, J.; Zhong, J.; Zhang, B.; Lu, S. Telocinobufagin inhibits the epithelial-mesenchymal transition of breast cancer cells through the phosphoinositide 3-kinase/protein kinase B/extracellular signal-regulated kinase/Snail signaling pathway. Oncol. Lett.; 2018; 15, pp. 7837-7845. [DOI: https://dx.doi.org/10.3892/ol.2018.8349]
39. Li, M.; Wang, Y.; Li, M.; Wu, X.; Setrerrahmane, S.; Xu, H. Integrins as attractive targets for cancer therapeutics. Acta Pharm. Sin. B; 2021; 11, pp. 2726-2737. [DOI: https://dx.doi.org/10.1016/j.apsb.2021.01.004]
40. Zhang, F.; Li, C.; Halfter, H.; Liu, J. Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells. Oncogene; 2003; 22, pp. 894-905. [DOI: https://dx.doi.org/10.1038/sj.onc.1206158]
41. Tolomeo, M.; Cascio, A. The multifaced role of STAT3 in cancer and its implication for anticancer therapy. Int. J. Mol. Sci.; 2021; 22, 603. [DOI: https://dx.doi.org/10.3390/ijms22020603] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33435349]
42. Zhang, F.; Wang, Z.; Fan, Y.; Xu, Q.; Ji, W.; Tian, R.; Niu, R. Elevated STAT3 signaling-mediated upregulation of MMP-2/9 confers enhanced invasion ability in multidrug-resistant breast cancer cells. Int. J. Mol. Sci.; 2015; 16, pp. 24772-24790. [DOI: https://dx.doi.org/10.3390/ijms161024772] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26501276]
43. Li, Y.; Gan, C.; Zhang, Y.; Yu, Y.; Fan, C.; Deng, Y.; Zhang, Q.; Yu, X.; Zhang, Y.; Wang, L. et al. Inhibition of Stat3 signaling pathway by natural product pectolinarigenin attenuates breast cancer metastasis. Front. Pharmacol.; 2019; 10, 1195. [DOI: https://dx.doi.org/10.3389/fphar.2019.01195]
44. Visavadiya, N.P.; Keasey, M.P.; Razskazovskiy, V.; Banerjee, K.; Jia, C.; Lovins, C.; Wright, G.L.; Hagg, T. Integrin-FAK signaling rapidly and potently promotes mitochondrial function through STAT3. Cell Commun. Signal.; 2020; 18, 64. [DOI: https://dx.doi.org/10.1186/s12964-020-00577-y]
45. Zhan, X.; Wu, H.; Wu, H.; Wang, R.; Luo, C.; Gao, B.; Chen, Z.; Li, Q. Metabolites from Bufo gargarizans (Cantor, 1842): A review of traditional uses, pharmacological activity, toxicity and quality control. J. Ethnopharmacol.; 2020; 246, 112178. [DOI: https://dx.doi.org/10.1016/j.jep.2019.112178]
46. Hu, F.; Chen, J.; Chen, H.; Zhu, J.; Wang, C.; Ni, H.; Cheng, J.; Hu, X.; Cao, P. Chansu improves the respiratory function of severe COVID-19 patients. Pharmacol. Res. Mod. Chin. Med.; 2021; 1, 100007. [DOI: https://dx.doi.org/10.1016/j.prmcm.2021.100007]
47. Cho, H.J.; Jung, H.J. Cyclophilin A inhibitors suppress proliferation and induce apoptosis of MKN45 gastric cancer stem-like cells by regulating CypA/CD147-mediated signaling pathway. Int. J. Mol. Sci.; 2023; 24, 4734. [DOI: https://dx.doi.org/10.3390/ijms24054734]
48. Han, J.M.; Kim, H.L.; Jung, H.J. Ampelopsin inhibits cell proliferation and induces apoptosis in HL60 and K562 leukemia cells by downregulating AKT and NF-κB signaling pathways. Int. J. Mol. Sci.; 2021; 22, 4265. [DOI: https://dx.doi.org/10.3390/ijms22084265]
49. Han, J.M.; Choi, Y.S.; Dhakal, D.; Sohng, J.K.; Jung, H.J. Novel nargenicin A1 analog inhibits angiogenesis by downregulating the endothelial VEGF/VEGFR2 signaling and tumoral HIF-1α/VEGF pathway. Biomedicines; 2020; 8, 252. [DOI: https://dx.doi.org/10.3390/biomedicines8080252]
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Triple-negative breast cancer (TNBC) is a highly aggressive type of breast cancer and has a poor prognosis. As standardized TNBC treatment regimens cause drug resistance and tumor recurrence, the development of new TNBC treatment strategies is urgently required. Bufotalin is a bufadienolide isolated from the skin and parotid venom glands of the toad Bufo gargarizan, and has several pharmacological properties, including antiviral, anti-inflammatory, and anticancer activities. However, the anticancer effect and underlying molecular mechanisms of action of bufotalin in TNBC have not been fully studied. In the current study, we investigated the effects of bufotalin on the growth and metastasis of MDA-MB-231 and HCC1937 TNBC cells. Bufotalin potently inhibited the proliferation of both TNBC cell lines by promoting cell cycle arrest and caspase-mediated apoptosis. Furthermore, bufotalin effectively suppressed the migration and invasion of both TNBC cell lines by regulating the expression of key epithelial-mesenchymal transition (EMT) biomarkers, matrix metalloproteinases (MMPs), and integrin α6. Notably, the anticancer effect of bufotalin in TNBC cells was associated with the downregulation of the signal transducer and activator of the transcription 3 (STAT3) signaling pathway. Collectively, our results suggest that the natural compound bufotalin may exert antiproliferative and antimetastatic activities in TNBC cells by modulating the apoptotic pathway and the STAT3/EMT axis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Hye Jin Jung 2
1 Department of Life Science and Biochemical Engineering, Graduate School, Sun Moon University, Asan 31460, Republic of Korea;
2 Department of Life Science and Biochemical Engineering, Graduate School, Sun Moon University, Asan 31460, Republic of Korea;